Trade Secret or Patent: Which Protects Your Invention?

The trade secret vs patent decision turns on one question before any other: can a competitor figure out how your invention works by buying your product and taking it apart? If yes, a trade secret will not survive, because reverse engineering is a lawful way to acquire it, and a patent is the only route to exclusivity. If no, because the invention is a process that runs inside your facility or an algorithm that never leaves your servers, a trade secret may protect it for longer than a patent ever could, at a fraction of the cost. Most real products contain both kinds of components, and the answer is usually a split rather than a choice. CLP’s trade secret protection practice works through that split with clients, and coordinates with patent counsel where the patent side is in play.

What each one gives you

A utility patent grants the right to exclude others from making, using, selling, or importing the claimed invention for twenty years from the filing date. It is enforceable against everyone, including a competitor who independently developed the same thing and had never heard of you. In exchange, the application is published, usually eighteen months after filing, and the patent itself teaches the public how to practice the invention. When the term ends, anyone may use it.

A trade secret grants the right to stop misappropriation: acquisition by improper means, or use or disclosure in breach of a duty of confidence. It has no fixed term and no filing. It is not enforceable against someone who reverse engineers the product or develops the same information independently. It lasts exactly as long as the information stays secret and the owner keeps taking reasonable measures to protect it, as explained in our post on what qualifies as a trade secret.

Trade secret vs patent: the factors that decide

Detectability of infringement

A patent is only as good as your ability to catch infringers. If the invention is a manufacturing process, you may never know a competitor is using it inside their plant, and a patent on it would be hard to enforce while telling the world exactly how to do it. That profile favors trade secret. If the invention is a visible product feature or a mechanism anyone can inspect, infringement is easy to detect and reverse engineering is easy, which favors a patent.

Expected useful life

A patent’s twenty-year term is generous for a pharmaceutical compound and irrelevant for a software feature that will be rewritten in three years. For short-lived inventions, the cost and delay of prosecution may not be worth it, and a combination of copyright, trade secret, and speed to market is more sensible. For inventions with value beyond twenty years, a trade secret is the only form of protection that can match that horizon, provided it can actually be kept secret that long.

Patentability

Not every invention qualifies. A patent requires that the invention be new, useful, non-obvious over the prior art, and eligible subject matter, and the eligibility bar for software and business methods has been high for more than a decade. If a patent is unlikely to issue, or would issue with claims so narrow they are easy to design around, trade secret protection may be the realistic option. A patentability assessment by a registered practitioner is the way to find out, and it should happen before any public disclosure.

Cost and timing

Patent prosecution involves drafting, filing, examination, responses to office actions, issue and maintenance fees, and often foreign filings in each country where protection is wanted. The process runs for years. Trade secret protection costs whatever the internal security program costs, which scales with the business and is spent anyway for other reasons. For a bootstrapped company, that difference can be decisive.

Risk of leakage

Trade secrets depend on people keeping quiet. A company with high employee turnover, many outside contractors, or manufacturing partners in several countries has more leak points than it can control. A patent does not care who knows the invention. If the information will inevitably be shared widely to be used, a patent is the safer bet.

The disclosure clock

The two routes are mutually exclusive for the same information once a patent application publishes, because publication destroys secrecy. Before that point, timing matters. In the United States, an inventor’s own public disclosure, sale, or public use starts a one-year clock to file; after that, a patent is barred. Most other countries have no grace period, so a disclosure before filing forfeits foreign rights immediately. A provisional application preserves a filing date for twelve months without publishing anything, which lets a company test the market while keeping both options open. A non-publication request can keep a U.S. application confidential until issuance if no foreign filing is planned, which delays the moment the trade secret alternative is lost.

There is also a defense for prior commercial users: a company that was commercially using an invention as a trade secret well before someone else filed a patent on it may have a limited defense to that patent in the United States. The defense is narrow and fact-dependent, and it is a reason to document when a secret process went into use.

Splitting a product between the two

In practice, the decision is made component by component. A medical device company might patent the mechanical design that is visible in the product, keep the manufacturing tolerances and the calibration process as trade secrets, and register copyright in the firmware. A software company might patent one novel method it can detect in competitors’ products, keep its training data and model weights as trade secrets, and register copyright in the source code, with the deposit redaction options described in our post on copyright registration for software. The published patent should be drafted so that it does not disclose the parts kept secret, which takes coordination between patent counsel and whoever manages the trade secret inventory. Our IP portfolio management page describes how those pieces are tracked together.

If you have an invention and are unsure which route fits, a consultation with Capitol Law Partners can run the factors above against your product and roadmap before any disclosure starts a clock. Schedule a consultation.

This article is for informational purposes only and does not constitute legal advice. No attorney-client relationship is formed by this communication.

Attorney Cagatay Ersoy. Practical strategy for founders, investors, and growing companies.

Need help with this topic? See our trade secret strategy and protection page or schedule a consultation.